As of 2026-06-19, the EV/EBITDA ratio of Myriad Genetics Inc (MYGN) is -35.31. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. MYGN's latest enterprise value is 409.59 mil USD. MYGN's TTM EBITDA according to its financial statements is -11.60 mil USD. Dividing these 2 quantities gives us the above MYGN EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 8.2x - 15.8x | 12.2x |
| Forward P/E multiples | 12.3x - 16.0x | 15.2x |
| Fair Price | (1.47) - (1.90) | (1.64) |
| Upside | -133.6% - -143.4% | -137.4% |
| Date | EV/EBITDA |
| 2026-06-15 | -34.82 |
| 2026-06-12 | -34.90 |
| 2026-06-11 | -37.35 |
| 2026-06-10 | -35.72 |
| 2026-06-09 | -36.61 |
| 2026-06-08 | -35.39 |
| 2026-06-05 | -36.86 |
| 2026-06-04 | -37.83 |
| 2026-06-03 | -35.47 |
| 2026-06-02 | -34.74 |
| 2026-06-01 | -34.50 |
| 2026-05-29 | -31.97 |
| 2026-05-28 | -34.01 |
| 2026-05-27 | -31.65 |
| 2026-05-26 | -30.99 |
| 2026-05-22 | -30.75 |
| 2026-05-21 | -31.48 |
| 2026-05-20 | -30.67 |
| 2026-05-19 | -28.55 |
| 2026-05-18 | -29.37 |
| 2026-05-15 | -28.80 |
| 2026-05-14 | -29.12 |
| 2026-05-13 | -30.02 |
| 2026-05-12 | -32.79 |
| 2026-05-11 | -33.93 |
| 2026-05-08 | -34.58 |
| 2026-05-07 | -32.95 |
| 2026-05-06 | -33.11 |
| 2026-05-05 | -40.60 |
| 2026-05-04 | -39.87 |
| 2026-05-01 | -38.73 |
| 2026-04-30 | -38.32 |
| 2026-04-29 | -37.75 |
| 2026-04-28 | -39.06 |
| 2026-04-27 | -38.97 |
| 2026-04-24 | -38.57 |
| 2026-04-23 | -38.65 |
| 2026-04-22 | -41.01 |
| 2026-04-21 | -40.28 |
| 2026-04-20 | -41.50 |
| 2026-04-17 | -41.01 |
| 2026-04-16 | -40.36 |
| 2026-04-15 | -41.90 |
| 2026-04-14 | -39.62 |
| 2026-04-13 | -37.02 |
| 2026-04-10 | -35.07 |
| 2026-04-09 | -35.80 |
| 2026-04-08 | -38.49 |
| 2026-04-07 | -38.24 |
| 2026-04-06 | -37.67 |